P Premoli1, M L Tanda1, E Piantanida1, G Veronesi2, D Gallo1, E Masiello1, S Rosetti1, C Cusini1, F Boi3, J Bulla3, R Rodia3, S Mariotti3, V Capelli4, M Rotondi4, F Magri4, L Chiovato4, R Rocchi5, M C Campopiano5, R Elisei5, P Vitti5, F Barbato6, T Pilli6, M G Castagna6, F Pacini6, L Bartalena7. 1. Department of Medicine and Surgery, University of Insubria, Endocrine Unit, Ospedale di Circolo, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varese, Italy. 2. Research Centre in Epidemiology and Preventive Medicine, University of Insubria, Varese, Italy. 3. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 4. Unit of Internal Medicine and Endocrinology, Istituti Clinici Scientifici Maugeri, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 5. Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 6. Endocrinology Unit, University of Siena, Siena, Italy. 7. Department of Medicine and Surgery, University of Insubria, Endocrine Unit, Ospedale di Circolo, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varese, Italy. luigi.bartalena@uninsubria.it.
Abstract
BACKGROUND: Whether differentiated thyroid cancer (DTC) occurring concomitantly with Graves' disease (GD) is more aggressive and bound to a less favorable outcome is controversial. OBJECTIVE: Aim of this multicenter retrospective study was to compare baseline features and outcome of DTC patients with GD (DTC/GD+) or without GD (DTC/GD-). PATIENTS: Enrolled in this study were 579 patients referred to five endocrine units (Cagliari, Pavia, Pisa, Siena, and Varese) between 2005 and 2014: 193 patients had DTC/GD+ , 386 DTC/GD-. Patients were matched for age, gender and tumor size. They underwent surgery because of malignancy, large goiter size, or relapse of hyperthyroidism in GD. RESULTS: Baseline DTC features (histology, lymph node metastases, extrathyroidal extension) did not differ in the two groups, except for multifocality which was significantly more frequent in DTC/GD+ (27.5% vs. 7.5%, p < 0.0001). At the end of follow-up (median 7.5 years), 86% of DTC/GD+ and 89.6% DTC/GD- patients were free of disease. Patients with persistent or recurrent disease (PRD) had "biochemical disease" in the majority of cases. Microcarcinomas were more frequent in the DTC/GD+ group (60% vs. 37%, p < 0.0001) and had an excellent outcome, with no difference in PRD between groups. However, in carcinomas ≥ 1 cm, PRD was significantly more common in DTC/GD+ (24.4% vs. 11.5%; p = 0.005). In the whole group, univariate and multivariate analyses showed that GD+ , lymph node involvement, extrathyroidal invasion, multifocality and tall cell histotype were associated with a worse outcome. Female gender and microcarcinomas were favorable features. No association was found between baseline TSH-receptor antibody levels and outcome. Graves' orbitopathy (GO) seemed to be associated with a better outcome of DTC, possibly because patients with GO may early undergo surgery for hyperthyroidism. CONCLUSIONS: GD may be associated with a worse outcome of coexisting DTC only if cancer is ≥ 1 cm, whereas clinical outcome of microcarcinomas is not related to the presence/absence of GD.
BACKGROUND: Whether differentiated thyroid cancer (DTC) occurring concomitantly with Graves' disease (GD) is more aggressive and bound to a less favorable outcome is controversial. OBJECTIVE: Aim of this multicenter retrospective study was to compare baseline features and outcome of DTCpatients with GD (DTC/GD+) or without GD (DTC/GD-). PATIENTS: Enrolled in this study were 579 patients referred to five endocrine units (Cagliari, Pavia, Pisa, Siena, and Varese) between 2005 and 2014: 193 patients had DTC/GD+ , 386 DTC/GD-. Patients were matched for age, gender and tumor size. They underwent surgery because of malignancy, large goiter size, or relapse of hyperthyroidism in GD. RESULTS: Baseline DTC features (histology, lymph node metastases, extrathyroidal extension) did not differ in the two groups, except for multifocality which was significantly more frequent in DTC/GD+ (27.5% vs. 7.5%, p < 0.0001). At the end of follow-up (median 7.5 years), 86% of DTC/GD+ and 89.6% DTC/GD- patients were free of disease. Patients with persistent or recurrent disease (PRD) had "biochemical disease" in the majority of cases. Microcarcinomas were more frequent in the DTC/GD+ group (60% vs. 37%, p < 0.0001) and had an excellent outcome, with no difference in PRD between groups. However, in carcinomas ≥ 1 cm, PRD was significantly more common in DTC/GD+ (24.4% vs. 11.5%; p = 0.005). In the whole group, univariate and multivariate analyses showed that GD+ , lymph node involvement, extrathyroidal invasion, multifocality and tall cell histotype were associated with a worse outcome. Female gender and microcarcinomas were favorable features. No association was found between baseline TSH-receptor antibody levels and outcome. Graves' orbitopathy (GO) seemed to be associated with a better outcome of DTC, possibly because patients with GO may early undergo surgery for hyperthyroidism. CONCLUSIONS: GD may be associated with a worse outcome of coexisting DTC only if cancer is ≥ 1 cm, whereas clinical outcome of microcarcinomas is not related to the presence/absence of GD.
Authors: E Masiello; G Veronesi; D Gallo; P Premoli; E Bianconi; S Rosetti; C Cusini; J Sabatino; S Ippolito; E Piantanida; M L Tanda; L Chiovato; W M Wiersinga; L Bartalena Journal: J Endocrinol Invest Date: 2018-06-26 Impact factor: 4.256
Authors: Louise Davies; Luc G T Morris; Megan Haymart; Amy Y Chen; David Goldenberg; John Morris; Jennifer B Ogilvie; David J Terris; James Netterville; Richard J Wong; Gregory Randolph Journal: Endocr Pract Date: 2015-06 Impact factor: 3.443
Authors: A Belfiore; M R Garofalo; D Giuffrida; F Runello; S Filetti; A Fiumara; O Ippolito; R Vigneri Journal: J Clin Endocrinol Metab Date: 1990-04 Impact factor: 5.958
Authors: L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera Journal: N Engl J Med Date: 1998-01-08 Impact factor: 91.245
Authors: Cari M Kitahara; Martha S Linet; Laura E Beane Freeman; David P Check; Timothy R Church; Yikyung Park; Mark P Purdue; Catherine Schairer; Amy Berrington de González Journal: Cancer Causes Control Date: 2012-07-29 Impact factor: 2.506
Authors: Carlo La Vecchia; Matteo Malvezzi; Cristina Bosetti; Werner Garavello; Paola Bertuccio; Fabio Levi; Eva Negri Journal: Int J Cancer Date: 2014-10-13 Impact factor: 7.396
Authors: Sami Akbulut; Khaled Demyati; Ridvan Yavuz; Nilgun Sogutcu; Emine Turkmen Samdanci; Yusuf Yagmur Journal: Ann Med Surg (Lond) Date: 2022-06-02
Authors: Jee Hee Yoon; Meihua Jin; Mijin Kim; A Ram Hong; Hee Kyung Kim; Bo Hyun Kim; Won Bae Kim; Young Kee Shong; Min Ji Jeon; Ho-Cheol Kang Journal: Endocrinol Metab (Seoul) Date: 2021-11-26
Authors: Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg Journal: Eur Thyroid J Date: 2022-01-01